Strategic partnerships Galimedix is actively engaging in ophthalmology and neurology partnerships, including with Laboratoires Théa SAS, signaling openness to co-development or milestone-driven collaborations that could expand distribution and accelerate access to their therapies.

Clinical expansion With Phase 2 clinical programs and recent preclinical data on next‑generation oral Alzheimer's candidates, there is potential for licensing, co‑development, or sponsored studies with pharma companies seeking late‑stage entry points or diversification of their CNS and eye disease portfolios.

Oral and topical focus The dual emphasis on oral small molecules and topical neuroprotective therapies creates cross‑selling opportunities across neurology and ophthalmology product lines, appealing to companies seeking integrative treatments for neurodegenerative diseases and eye disorders.

Milestone signals Milestone payments from Théa and ongoing preclinical/clinical data releases provide indicators of momentum and potential near‑term collaboration milestones that sales teams can align with targeted outreach and value propositions.

Tech and data readiness A cloud and web‑centric tech stack (AWS, Nginx, WordPress, etc.) suggests scalable digital outreach, partner portals, and data‑driven due diligence capabilities to support potential licensing, collaboration, and co‑development negotiations.